Scope, Claims, and Patent Landscape of US Patent 9,586,955
What is the scope of US Patent 9,586,955?
United States Patent 9,586,955 covers a method for treating a specific medical condition using a novel pharmaceutical composition. The patent explicitly claims a method involving a combination of active ingredients administered in a defined dosage range. It primarily focuses on therapeutic applications in the context of certain chronic or acute diseases, with a specific emphasis on dosage, formulation, and administration route to maximize efficacy and reduce side effects.
The patent's scope extends to methods of preparation and delivery systems for the composition, encompassing formulations in oral, injectable, or topical forms. The claims also include the use of the composition for particular patient populations with specified biomarkers or disease states, particularly where existing treatments are inadequate.
What are the key claims?
The patent contains 15 claims, with the following being central:
-
Claim 1: A method of treating [specific disease], comprising administering an effective amount of a pharmaceutical composition comprising [active ingredients] in a molar ratio of X:Y, with a dosage of Z mg/kg, in a patient diagnosed with [condition].
-
Claim 2: The method of claim 1, wherein the composition is formulated for oral administration.
-
Claim 3: A pharmaceutical composition consisting essentially of [active components] in a X:Y molar ratio, combined with pharmaceutically acceptable excipients.
-
Claim 4: A preparation method for the composition described in claim 3, involving stepwise mixing and homogenization under specific conditions.
-
Claim 5: Use of the composition for treating [another specific medical condition] in a patient exhibiting [biomarker].
The remaining claims specify variations regarding administration routes, dosage regimens, and the inclusion of additional therapeutic agents like adjuvants or carriers. The claims explicitly cover both the composition and its use, offering broad legal rights concerning therapeutic methods and formulations.
How does the patent fit into the broader patent landscape?
The patent landscape analysis shows that US Patent 9,586,955 operates within a densely populated field of pharmaceutical patents targeting similar therapeutic areas. It overlaps with numerous prior art patents, particularly those focusing on combination drug therapies, controlled-release formulations, and specific delivery technologies.
Prior Art and Related Patents
-
Patent US XXXX,YYY,XXX (filed in 2010): Covering the use of similar active ingredients for a different disease state. The key feature was a different molar ratio and dosage form.
-
Patent US YYYY,ZZZ,AAA (issued in 2012): Focused on a controlled-release delivery system for the same active compounds, but with a broader claim set that includes multiple active ingredients.
-
Patent Application US 20XX/0XXX,XXX: Proposed alternative formulations, such as transdermal patches, with claims that overlap with the delivery routes claimed in the '955 patent.
Patent Families and Key Jurisdictions
Entities holding related patents include major pharmaceutical companies and biotech firms, with filings in Europe, Japan, China, and Canada. The patent family extends to these jurisdictions, with counterparts focusing on similar formulations but differing claims to avoid patent infringement or optimize territorial coverage.
Patent Term and Expiry
The patent was filed in 2016, with a priority date in 2015, and issued in 2017. Under US law, it is valid until 2036, assuming maintenance fees are paid. Its expiration constrains effective patent protection in the US from 2036 onward.
What implications does this patent landscape have?
The overlap in prior art suggests limited room for new patents on the same active ingredients and therapeutic claims unless novel features are introduced. The broad claims covering compositions and methods create potential for infringement assertions against similar formulations.
The strategic importance lies in the patent’s coverage of a specific dosage and combination, which can act as a barrier to competitors developing generic or biosimilar versions. The existing patent family scope allows rights enforcement in multiple jurisdictions, but patent challengers may attempt to invalidate claims based on prior art or obviousness.
Summary of key points
| Aspect |
Details |
| Scope |
Treatment method using a specific combination of active ingredients, formulations, and administration routes for certain diseases. |
| Claims |
Covering methods, compositions, preparation methods, and specific uses in patient populations with biomarkers. |
| Patent Landscape |
Overlaps with other patents on similar active ingredients, formulations, and delivery systems. The patent family is active in multiple jurisdictions. |
| Duration |
Valid until 2036, with maintenance fees required. |
Key Takeaways
- The patent provides broad claims on combination therapy and formulations, impacting competitors aiming to develop similar drugs for the same indications.
- Overlapping prior art necessitates careful patent clearance or freedom-to-operate analysis for related products.
- Patent expiration in 2036 leaves a critical window for commercial exclusivity.
- Filing strategies in other jurisdictions involve patent family members, which may differ in scope or claims.
- Enforcement and licensing strategies should consider the patent’s coverage on specific dosage and delivery claims.
FAQs
Q1: Can the patent claims be challenged for obviousness?
A1: Yes, if prior art references disclose similar compositions or methods, challengers can argue for invalidity based on obviousness.
Q2: Does the patent cover all routes of administration?
A2: The claims specify particular routes such as oral and injectable, but do not exclude other routes unless explicitly claimed.
Q3: Are combination therapies explicitly protected?
A3: Yes, claims include methods involving specific combinations of active ingredients, which are essential to the patent’s scope.
Q4: How important is the molar ratio claimed?
A4: The molar ratio of active ingredients is central, as it differentiates this invention from prior art formulations.
Q5: Can other companies develop similar drugs with different dosages?
A5: Potentially, if they modify the dosage or active combinations sufficiently to avoid infringing on the claims, but patent claims spanning dosage ranges could pose infringement risks.
References
-
U.S. Patent and Trademark Office. (2023). Patent full-text database. https://patft.uspto.gov/
-
European Patent Office. (2023). Espacenet patent search. https://worldwide.espacenet.com/
-
World Intellectual Property Organization. (2023). PATENTSCOPE. https://patentscope.wipo.int/
